CD3G and cancer: The results showed that has-miR-378, which was a miRNA predicted for CD3G, had increased in all blood sera belonging to patients suffering from castration resistant prostate cancer (CRPC) [38], renal cell carcinoma (RCC) [16], [39] and gastric cancer (GC) [40]; besides, cancer tissues in patients with bladder cancer (BC) [41], carcinoma basal cells [42], colorectal cancer (CRC) [43], oral carcinoma [44], laryngeal carcinoma [45] and gastric cancer [46].